Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab in Limited-Stage Small Cell Lung Cancer
NCT07381543Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2026
- Primary completion
- Aug 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of adebrelimab in small cell lung cancer (SCLC) (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Progression-Free Survival at 3 years. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07381543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07381543.